Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging

Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central ne...

Full description

Saved in:
Bibliographic Details
Published inCase Reports in Cardiology Vol. 2019; no. 2019; pp. 1 - 3
Main Authors Radwan, Sohab S., Schwartz, Owen G.
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2019
Hindawi
John Wiley & Sons, Inc
Hindawi Limited
Subjects
Adenosine
Cardiology
Case Report
Case reports
Complications and side effects
Convulsions & seizures
Coronary heart disease
Coronary vessels
Disease susceptibility
Electrocardiography
Heart rate
Ischemia
Levetiracetam
Medical imaging
Medical research
Medicine, Experimental
NMR
Nuclear magnetic resonance
Nuclear medicine
Patients
Seizures (Medicine)
Smooth muscle
Veins & arteries
United States > US
Online AccessGet full text

Cover

More Information
Summary:Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central nervous system (CNS) including the cerebral cortex, hippocampus, and other structures as well, regadenoson can lower the seizure threshold in susceptible individuals. Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson use, and therefore, more awareness is required in screening patients at risk and evaluating alternate ways to investigate coronary artery disease (CAD) in susceptible individuals.
Bibliography:Academic Editor: Assad Movahed
ISSN:2090-6404
2090-6412
DOI:10.1155/2019/6240605